Ziopharm Oncology, Inc. (ZIOP) stock fell down by 7.41% in the after-hours, shedding its day’s gains, on December 17. The stock seems to be under corrections since it gained over 14.4% in regular trading.
During regular trading, the stock increased by $0.17 at its closing price of $1.35 at 5.38 million shares. The stock fell down to $1.25 at an after-hours’ volume of 634.15 thousand shares, under corrections.
ZIOP stock and its Movement
The biopharmaceutical company Ziopharm Oncology, Inc. has a market capitalization of $291.8 million. Currently, the company has 216.15 million shares outstanding in the market.
In the previous market session, ZIOP stock became bullish and gained a good amount with no recent news from the company. The hike in the stock resulted in its five-day gain to reach 10.66%. After gaining over 14.4%, the stock entered red in the after-hours and started shedding its gain. Hence, ZIOP fell under stock correction after the regular session closed on Friday.
Preclinical Data Presentation
On November 13, the company presented its preclinical data at the Society for Immunotherapy of Cancer 2021 Annual Meeting. The data highlighted neoantigen-specific TCR-T cells’ potential in treating solid tumors.
The company developed the specific neoantigen/HLA using its Sleeping Beauty technology. Sleeping Beauty is a non-viral gene transfer technology of ZIOP. Moreover, the ZIOP’s TCR-T library can develop safe and effective therapies for patients whose neoantigen/HLA combination matches it. Currently, the company is working on the initiation of Phase ½ TCR-T Library trail in the first half of 2022. Furthermore, ZIOP is also working on the expansion of its TCRs library for increasing its pool of eligible patients.
ZIOP’s Financial Analysis
On November 08, the company announced its financial results for the third quarter which ended on September 30, 2021. In the Q3 of 2021, ZIOP has research and development expenses of $14.5 million. Comparatively, the R&D expenses were $14.0 million in the same quarter of 2020.
Moreover, the company had general and administrative expenses of $8.2 million in the Q3 of 2021. This increased 29% from $6.4 million in the third quarter of 2020.
Furthermore, the company incurred a net loss of $22.7 million in Q3 of 2021, against $20.3 million in Q3 of 2020. Consequently, the net loss per basic and diluted share were $0.11 and $0.10 in the third quarter of 2021, and 2020, respectively.
